News | April 07, 2010

Defibrillator Maker Pleads Guilty to Not Reporting Safety Problems

April 7, 2010 – A medical manufacturer pleaded guilty Monday to criminal violations for improper reporting of short-circuit failures of three models of its implantable cardioverter defibrillators (ICDs), the Justice Department announced. The company also agreed to pay more than $296 million in damages.

Guidant LLC admitted criminal wrongdoing after a four-year investigation into its handling of the short-circuiting failures. The ICD models include the Ventak? Prizm 2 DR (Model 1861) and the Contak Renewal (Models H135 and H155). Guidant’s ?Cardiac Rhythm Management division, which produced the defibrillators, is headquartered in ?Arden Hills, Minnesota. Guidant is now owned by Boston Scientific.

“The entry of a guilty plea by Guidant and the proposed resolution would?represent the largest criminal penalty ever imposed on a device manufacturer for violating the Food Drug and Cosmetic Act,” said Commissioner of Food and Drugs Margaret A. Hamburg,?M.D. “The FDA will continue to commit enforcement resources to seeking this type of criminal resolution and stiff sanctions when device manufacturers fail to adhere to the statutory and?regulatory requirements that exist to ensure the safety and efficacy of their products.”

The plea was made in St. Paul, Minn., before U.S.?District Court Judge Donovan W. Frank. Under the terms of the plea agreement with the Justice Department to resolve the charges,?which must still be approved by Judge Frank, Guidant pleaded guilty to with holding?information from the U.S. Food and Drug Administration (FDA) regarding catastrophic failures?in some of its devices. Specifically, Guidant admitted to: 1) making a materially false?statement in a required submission to the FDA with regard to the Ventak Prizm 2DR device; and?(2) failing to notify the FDA of a "correction" to the Contak Renewal devices, which the?company made to reduce a risk to health caused by the devices. As a result of these offenses, the agreement calls for Guidant to pay a combined criminal penalty in excess of $296 million.

“Guidant’s guilty plea today is about accountability,” said Assistant Attorney General?Tony West, who heads the Justice Department’s Civil Division. “This successful prosecution?serves as an important wake up call to all those who seek to withhold vital information about?public health and safety. We will continue our efforts to prosecute those who jeopardize public?health by evading their reporting obligations to the FDA.”

“The guilty plea today should serve as a reminder and deterrent to those who would?break the laws requiring honesty and cooperation with government regulators whose mission is?to protect the health and safety of the public,” said Frank J. Magill, Acting U.S. Attorney in this?case for the District of Minnesota. “The health care laws are as important as ever. When?medical device and pharmaceutical companies fail to live up to their legal obligations, serious?criminal consequences will follow.”

Related Content

Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD)| September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD)| September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Predictive Models May Help Determine Which Patients Benefit From ICDs
News | Implantable Cardioverter Defibrillator (ICD)| July 06, 2017
Two predictive models may help cardiologists decide which patients would most benefit from an implantable cardioverter...
Videos | Implantable Cardioverter Defibrillator (ICD)| June 01, 2017
Lucas Boersma, M.D., Ph.D., FESC, St.
The Unify ICD is one of the SJM devices in an FDA warning letter
Feature | Implantable Cardioverter Defibrillator (ICD)| April 14, 2017 | Dave Fornell
April 14, 2017 — The U.S. Food and Drug Administration (FDA) sent a warning letter to Abbott/St.
ICDs, non-ischemic cardiomyopathy, University of Alabama at Birmingham study, Circulation
News | Implantable Cardioverter Defibrillator (ICD)| January 18, 2017
A new study published in Circulation has found there is a 23 percent risk in reduction of all-cause mortality in non-...
ICDs, implantable cardioverter defibrillators, survival rate, elderly patients, JACC study
News | Implantable Cardioverter Defibrillator (ICD)| January 17, 2017
Of patients over age 65 who received an implantable cardioverter-defibrillator (ICD) after surviving sudden cardiac...
Overlay Init